Dr. No

A Few Lessons From Exubera

The challenge for a large pharma and a single product biotech company is to be able to manage expectations on the market with respect to their pipeline. Doing it appropriately would reduce micro and macro attractivity of the biotech sector to apprpriate levels, bad for stock price though. In the mix of interdependent banker, analysts and company employees now one has an incentive to be realistic in a short term world with respect to long-term projections. That is the underlying behavioral pattern.